Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05460975

Breast Cancer Risk From Sonographic Glandular Tissue Component (or International GTC Study)

An international multicenter study to prospectively validate the association between sonographic GTC and subsequent breast cancer risk in women with dense breasts.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–69 year

Sex eligibility

Female

Study type

Observational

Primary location

Seoul National University Hospital

Seoul, South Korea

Location status: Recruiting

Location contact

Woo Kyung Moon

CONTACT

About this study

Women with similarly dense breasts on mammography may have different subsequent risks of developing breast cancer due to varying degrees of lobular involution. Breast ultrasound (US) can assess the relative amount of glandular tissue component (GTC) to the fibrous stroma in dense breast parenchyma and can reflect the amount of terminal duct lobular units (TDLU) as seen in histology. In women with dense breasts on mammography, an association between high levels of sonographic GTC, defined as the percent of glandular tissue within fibroglandular tissue, and an increased risk of breast cancer was demonstrated in a retrospective single-center study of 8483 Korean women. The purpose of this international multicenter study is to prospectively validate whether sonographic GTC is associated with subsequent breast cancer risk and whether it can provide additional information beyond established risk factors. In this study, investigators will enroll 16164 women with dense breasts (BI-RADS density categories C and D on mammography) undergoing screening breast US using either an automated or handheld device. GTC will be assessed qualitatively as minimal, mild, moderate, or marked at the time of US interpretation and will be dichotomized into low (minimal or mild) versus high (moderate or marked). The primary outcome is a pathologic diagnosis of breast cancer, including invasive cancer and ductal carcinoma in situ (DCIS). Women are observed from 3 months after date of GTC assessment to breast cancer diagnosis or censoring as a result of death or end date of complete cancer capture. Covariate information will be obtained from self-report at the time of breast US examination and includes age, race/ethnicity, menopausal status, first-degree family history of breast cancer, breast density, history of benign breast biopsy, BMI, age at first live birth, and hormone replacement therapy (HRT) usage. The 5-year cumulative incidence of breast cancer by level of sonographic GTC will be compared based on marginal standardization with the predicted risk summed to a weighted risk according to the observed covariate distribution in the study population. The association of sonographic GTC with breast cancer risk will be estimated by using the Fine-Gray subdistribution hazards model to account for the competing risk of death. In addition, investigators will compare the discriminatory accuracy of the breast cancer surveillance consortium (BCSC) 5-year risk score and the BCSC model integrated with sonographic GTC.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • be ≥ 40 and <70 years old at time of US
  • No history of previous breast cancer including DCIS
  • have dense breasts (BI-RADS category C and D on mammography performed within 12 months of breast US) and negative/benign BI-RADS assessment categories on mammography (BI-RADS 1, 2)
  • undergoing screening breast US using either automated or handheld device

Exclusion criteria

  • history of bilateral prophylactic mastectomy
  • history of bilateral foreign body injection
  • history of bilateral breast implants
  • history of bilateral breast reduction surgery or surgical excision
  • currently pregnant or breast feeding in the preceding 6 months
  • Known distant metastasis from other primary cancer

Treatment and study plan

Primary outcomes

  1. Incident breast cancer within 3 months to 7 years after the assessment of sonographic GTC

    Time frame: from 3 months to 7 years after the GTC assessment

    The 5-year cumulative incidence of breast cancer and hazard ratio by level of sonographic GTC using standardized risk

Secondary outcomes

  1. Correlation of sonographic GTC with risk according to tumor type

    Time frame: from 3 months to 7 years after the GTC assessment

    Correlation of sonographic GTC with risk according to tumor type (DCIS vs. invasive cancer)

  2. Correlation of sonographic GTC with breast cancer according to the breast US device

    Time frame: from 3 months to 7 years after the GTC assessment

    Correlation of sonographic GTC with breast cancer according to the breast US device (hand-held vs. automated)

  3. The expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy)

    Time frame: from 3 months to 7 years after the GTC assessment

    The expected-to-observed (E/O) number of cancer diagnoses and concordance index (discriminatory accuracy) for the BCSC model (5-year risk score) and BCSC model integrated with sonographic GTC

  4. Breast US diagnostic performance according to sonographic GTC

    Time frame: from the examination till 1 year after the GTC assessment

    Sensitivity, specificity, positive predictive value

Study contacts

Contact information is provided by the study sponsor or research team.

Woo Kyung Moon, MD, PhD

CONTACT

[email protected]

+82220722584

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Registry information

Official study title

Association of Sonographic Glandular Tissue Component With Breast Cancer Risk Among Women With Dense Breasts: A Prospective, Multinational Validation Study

Important dates

Study start
2022
Primary completion
2026
Study completion
2031
First posted
Jul 15, 2022
Registry last updated
Jun 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.